309 related articles for article (PubMed ID: 20637892)
1. Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription.
Ampofo E; Kietzmann T; Zimmer A; Jakupovic M; Montenarh M; Götz C
Int J Biochem Cell Biol; 2010 Oct; 42(10):1729-35. PubMed ID: 20637892
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner.
Flügel D; Görlach A; Michiels C; Kietzmann T
Mol Cell Biol; 2007 May; 27(9):3253-65. PubMed ID: 17325032
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of HIF-1alpha by oncolytic reovirus infection independently of VHL and p53.
Cho IR; Koh SS; Min HJ; Park EH; Ratakorn S; Jhun BH; Jeong SH; Yoo YH; Youn HD; Johnston RN; Chung YH
Cancer Gene Ther; 2010 May; 17(5):365-72. PubMed ID: 20075985
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
5. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
Paltoglou S; Roberts BJ
Oncogene; 2007 Jan; 26(4):604-9. PubMed ID: 16862177
[TBL] [Abstract][Full Text] [Related]
6. Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.
Frost J; Rocha S; Ciulli A
J Biol Chem; 2021 Aug; 297(2):100910. PubMed ID: 34174286
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha.
Kong X; Lin Z; Liang D; Fath D; Sang N; Caro J
Mol Cell Biol; 2006 Mar; 26(6):2019-28. PubMed ID: 16507982
[TBL] [Abstract][Full Text] [Related]
8. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
9. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level.
Hubert A; Paris S; Piret JP; Ninane N; Raes M; Michiels C
J Cell Sci; 2006 Aug; 119(Pt 16):3351-62. PubMed ID: 16882692
[TBL] [Abstract][Full Text] [Related]
10. HIF-1α Hydroxyprolines Modulate Oxygen-Dependent Protein Stability Via Single VHL Interface With Comparable Effect on Ubiquitination Rate.
He W; Batty-Stuart S; Lee JE; Ohh M
J Mol Biol; 2021 Nov; 433(22):167244. PubMed ID: 34537235
[TBL] [Abstract][Full Text] [Related]
11. TCTP increases stability of hypoxia-inducible factor 1α by interaction with and degradation of the tumour suppressor VHL.
Chen K; Chen S; Huang C; Cheng H; Zhou R
Biol Cell; 2013 May; 105(5):208-218. PubMed ID: 23387829
[TBL] [Abstract][Full Text] [Related]
12. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity.
Lewis MD; Roberts BJ
Oncogene; 2004 Mar; 23(13):2315-23. PubMed ID: 14691445
[TBL] [Abstract][Full Text] [Related]
13. Role of the von Hippel-Lindau tumour suppressor protein in the regulation of HIF-1alpha and its oxygen-regulated transactivation domains at high cell density.
Paltoglou SM; Roberts BJ
Oncogene; 2005 May; 24(23):3830-5. PubMed ID: 15750626
[TBL] [Abstract][Full Text] [Related]
14. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
15. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.
Liu YV; Baek JH; Zhang H; Diez R; Cole RN; Semenza GL
Mol Cell; 2007 Jan; 25(2):207-17. PubMed ID: 17244529
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
17. Alternative regulation of HIF-1α stability through Phosphorylation on Ser451.
Han HJ; Saeidi S; Kim SJ; Piao JY; Lim S; Guillen-Quispe YN; Choi BY; Surh YJ
Biochem Biophys Res Commun; 2021 Mar; 545():150-156. PubMed ID: 33550096
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564.
Harada H; Kizaka-Kondoh S; Hiraoka M
FEBS Lett; 2006 Oct; 580(24):5718-22. PubMed ID: 17010341
[TBL] [Abstract][Full Text] [Related]
19. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Knauth K; Bex C; Jemth P; Buchberger A
Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
